TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Science

    PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

    PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    Advertise

    Copyright: © 2018

    • Apple Podcasts
    • Google Play
    • Spotify
    Latest Episodes:
    Darren McGuire, MD, MHSc - Translating Data Into Practice: Examining the Impact of Weight Loss Pharmacotherapy on Cardiovascular Outcomes Dec 12, 2023
    Show notes

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/UGE865. CME credit will be available until December 5, 2024.

    Translating Data into Practice: Examining the Impact of Weight Loss Pharmacotherapy on Cardiovascular Outcomes

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by an educational grant from Novo Nordisk Inc.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Darren McGuire, MD, MHSc, has a financial interest/relationship or affiliation in the form of:
    Other Financial or Material Support in the form of clinical trial leadership for AstraZeneca; CSL Behring; and Esperion Therapeutics, Inc.

    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    Thomas G. Martin, III, MD - The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms Dec 12, 2023
    Show notes

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/NRA865. CME/MOC/NCPD/IPCE credit will be available until November 29, 2024.

    The A-Team Against Relapsed/Refractory Myeloma: Community Strategies for Enhancing Outcomes With Potent CD38 Antibody Platforms

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by an educational grant from Sanofi.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Thomas G. Martin, III, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for GlaxoSmithKline and Pfizer.
    Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; and Sanofi.

    Faculty/Planner
    Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.

    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    Josep Tabernero, MD, PhD / Shubham Pant, MD - Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care Dec 06, 2023
    Show notes

    For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PZU865. CME/NCPD/CPE/AAPA/IPCE credit will be available until November 27, 2024.

    Elevating Outcomes for HER2-Expressing GI Cancers: The Evolving Role of Molecularly Targeted Agents in BTC and GEA Care

    In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Cholangiocarcinoma Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Co-Chair/Planner
    Josep Tabernero, MD, PhD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Cardiff Oncology, Inc.; CARsgen Therapeutics; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Genentech Inc; hC Bioscience, Inc.; Ikena Oncology; Inspirna, Inc.; Lilly; Menarini; Merck Serono; Merck Sharp & Dohme; Merus; Mirati Therapeutics Inc.; NeoPhore; Novartis AG; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology A/S; Scorpion Therapeutics; Seagen; Servier; SOTIO Biotech AG; Taiho; Takeda Oncology, ; and TOLREMO Therapeutics AG.
    Stock Shareholder in Oniria Therapeutics, Alentis Therapeutics, Pangaea Oncology and 1TRIALSP.

    Co-Chair/Planner
    Shubham Pant, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AskGene Pharma Inc.; Boehringer Ingelheim International GmbH; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Zymeworks Inc.
    Grant/Research Support from 4D Pharma; Amal Therapeutics; Arcus Biosciences; Astellas Pharma Inc.; BioNTech; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Elicio Therapeutics; Immuneering Corporation; ImmunoMET; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; NGM Biopharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer; Purple Biotech; Rgenix; Xencor; and Zymeworks Inc. All goes to Institution.

    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    Dan Atkins, MD - Facing the Challenges of EoE Head On: A Game Plan for Diagnosis and Integrating Targeted Therapy Using a Team Approach Dec 06, 2023
    Show notes

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKS865. CME/MOC/AAPA credit will be available until November 13, 2024.

    Facing the Challenges of EoE Head On: A Game Plan for Diagnosis and Integrating Targeted Therapy Using a Team Approach

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Dan Atkins, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for The American Partnership for Eosinophilic Disorders (APFED) and CURED.

    Patient/Planner
    Valira Pietrangelo has no financial interests/relationships or affiliations in relation to this activity.

    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    Beth Sandy, MSN, CRNP, FAPO - Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care Dec 06, 2023
    Show notes

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

    For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CE/CPE/AAPA information, and to apply for credit, please visit us at PeerView.com/BUC865. CME/NCPD/CE/CPE/AAPA credit will be available until December 9, 2024.

    Antibody–Drug Conjugates, the Ultimate Weapons Against Solid Tumors: Latest Progress, Future Possibilities, and Implications for Patient Care

    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Support
    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

    Faculty/Planner Disclosures
    Chair/Planner
    Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.
    Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.

    Faculty/Planner
    Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
    Speakers Bureau participant with Horizon CME and OncLive.

    Faculty/Planner
    Elizabeth Prechtel Dunphy, DNP, RN, ANP-BC, AOCN, has a financial interest/relationship or affiliation in the form of:
    Speakers Bureau participant with Incyte.

    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    James F. Howard Jr., MD - FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application Dec 01, 2023
    Show notes

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
    For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/NYF865. CME/NCPD/CPE/IPCE credit will be available until November 6, 2024.
    FcRn Modulation as a Targeted Approach to Myasthenia Gravis Management: From Pathophysiologic Rationale to Practical Application
    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
    Support
    This activity is supported by an educational grant from argenx US, Inc.
    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
    Faculty/Planner Disclosures
    Chair/Planner
    James F. Howard Jr., MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Alexion Pharmaceuticals, Inc.; Argenx; Biologix Pharma; F. Hoffmann-La Roche Ltd.; Horizon Therapeutics plc; Immunovant, Inc.; Merck & Co., Inc./EMD Serono, Inc.; NMD Pharma A/S; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals, Inc./UCB Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; Toleranzia AB; and Zai Lab.
    Grant/Research Support from Alexion Pharmaceuticals, Inc.; Argenx; Cartesian Therapeutics, Inc.; and Ra Pharmaceuticals, Inc./UCB Inc.
    Speaker for Alexion Pharmaceuticals, Inc.; Argenx; F. Hoffmann-La Roche Ltd; and Zai Lab.
    Faculty/Planner
    Amy Clarke, MSN, RN, IgCN, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Grifols, S.A.; Kedrion Biopharma Inc.; Koru Pharma Co., LTD; Pfizer; and Takeda Pharmaceutical Company Limited.
    Faculty/Planner
    Claire Spahn, PharmD, BCPS, has no financial interests/relationships or affiliations in relation to this activity.
    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    Javier Morales, MD, FACP, FACE / Jay H. Shubrook, DO, FAAFP, FACOFP - Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM Dec 01, 2023
    Show notes

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
    For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/XCX865. CME/AAPA credit will be available until November 26, 2024.
    Cases in the Community: Optimizing Treatment and Considering Weight Management as a Primary Goal in People With T2DM
    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
    Support
    This activity is supported by an educational grant from Lilly.
    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
    Faculty/Planner Disclosures
    Co-Chair/Planner
    Javier Morales, MD, FACP, FACE, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc.
    Speaker for Amgen Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Lilly; and Novo Nordisk Inc.
    Co-Chair/Planner
    Jay H. Shubrook, DO, FAAFP, FACOFP, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Abbott; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Lilly; Nevro Corp.; and Novo Nordisk Inc.
    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    Mrinal Gounder, MD - Getting to Know the New Desmoid Tumor ICD-10-CM Codes and Why They Matter: Practical Guidance for Integrating the New Codes and Navigating the Implications Dec 01, 2023
    Show notes

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
    For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/YNP865. CME credit will be available until November 26, 2024.
    Getting to Know the New Desmoid Tumor ICD-10-CM Codes and Why They Matter: Practical Guidance for Integrating the New Codes and Navigating the Implications
    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
    Support
    This activity is supported by an independent medical education grant from SpringWorks Therapeutics, Inc.
    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
    Faculty/Planner Disclosures
    Chair/Planner
    Mrinal Gounder, MD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Aadi bioscience; Ayala Pharmaceuticals; Bayer AG; Boehringer Ingelheim Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Epizyme; Karyopharm Therapeutics; Rain Therapeutics; Regeneron Pharmaceuticals Inc.; SpringWorks Therapeutics; and TYME Inc.
    Grant/Research Support from Ayala Pharmaceuticals; Bayer AG; Iterion Therapeutics; and SpringWorks Therapeutics.
    Faculty/Planner
    Linda Holtzman, MHA, RHIA, CCS, CCS-P, CPC, COC, has a financial interest/relationship or affiliation in the form of:
    Other Financial or Material Support as an Independent Contractor for Desmoid Tumor Research Foundation.
    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    James D. Berry, MD, MPH - Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options Nov 24, 2023
    Show notes

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
    For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/FCQ865. CME/AAPA credit will be available until December 15, 2024.
    Making the Most of Advances in Amyotrophic Lateral Sclerosis: Strategies to Improve Early Diagnosis and Maximize the Benefit of Novel Treatment Options
    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
    Support
    This activity is supported by educational grants from Amylyx Pharmaceuticals, Inc. and Sanofi.
    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
    Faculty/Planner Disclosures
    Co-Chair/Planner
    James D. Berry, MD, MPH, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc. and Biogen.
    Grant/Research Support from Alexion Pharmaceuticals, Inc.; Amylyx Pharmaceuticals, Inc.; Brainstorm Cell Therapeutics Ltd.; Mitsubishi Tanabe Pharma America, Inc.; nQ Medical; and Rapa Therapeutics.
    Data Safety Monitoring Board for Sanofi.
    Co-Chair/Planner
    Sabrina Paganoni, MD, PhD, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for Amylyx Pharmaceuticals, Inc.; Arrowhead Pharmaceuticals, Inc.; Cytokinetics, Incorporated; and Orion Corporation.
    Grant/Research Support from Alector, Inc.; Amylyx Pharmaceuticals, Inc.; Biohaven, Ltd.; Calico Life Sciences LLC; Clene Nanomedicine, Inc.; Denali Therapeutics; DoD; National Institutes of Health (NIH); Prilenia Therapeutics; Seelos Therapeutics, Inc.; and UCB, Inc.
    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    Claudia A. Chiriboga, MD, MPH, FAAN - Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood Nov 24, 2023
    Show notes

    This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.
    For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CRG865. CME/AAPA credit will be available until November 5, 2024.
    Building a Better Bridge: Providing Continuous SMA Care From Adolescence Through Adulthood
    In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
    Support
    This activity is supported by an educational grant from Genentech, a member of the Roche Group.
    Disclosure Policy
    All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
    Faculty/Planner Disclosures
    Chair/Planner
    Claudia A. Chiriboga, MD, MPH, FAAN, has a financial interest/relationship or affiliation in the form of:
    Consultant and/or Advisor for F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis.
    Grant/Research Support from Biogen; Biohaven, Ltd.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; and Novartis Pharmaceuticals Corporation/AveXis.
    Planning Committee and Reviewer Disclosures
    Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

    Previous 1 60 61 62 63 64 106 Next

    Related Podcasts

    Invisibilia

    1

    Invisibilia Personal Journals
    Hidden Brain – Hidden Brain, Shankar Vedantam

    2

    Hidden Brain – Hidden Brain, Shankar Vedantam Science
    How To Do Everything

    3

    How To Do Everything Science
    Hidden Brain

    4

    Hidden Brain Games & Hobbies
    Something You Should Know

    5

    Something You Should Know Education
    Sword and Scale – Sword and Scale

    6

    Sword and Scale – Sword and Scale Alternative Health
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights